PADRE peptide

Overview

PADRE peptide is a pan- HLA-DR binding epitope and immunostimulant. PADRE peptide binds to the peptide-binding groove of MHC class II molecules for presentation to CD4 + T cells, thereby effectively stimulating specific immune responses. PADRE peptide not only enhances anti-tumor immune responses, inhibits tumor growth and prolongs survival; it also significantly increases the frequency of E7 -specific CD8 + T cells and improves therapeutic efficacy against TC-1 tumors when used in combination with E7 peptide-based vaccines and poly (I:C) . The intensity of the immune response induced by PADRE peptide is lower than that of the Ii-PADRE DNA vaccine, and it fails to enhance the immune effect of CRT-E7 DNA . PADRE peptide is widely applicable to research on related tumors such as melanoma, glioblastoma and cervical cancer .

Application

Products | Products > Peptides | Products > Disease Areas > Cervical Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Glioblastoma | Products > Disease Areas > Cancer | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > CNS Neoplasm | Products > Disease Areas > Glioma | Products > Signaling Pathways > Immunology/Inflammation | Products > Research Areas > Neurological Disease | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Signaling Pathways > CD74 | Products > Signaling Pathways > MHC

Product Information

• Catalog No.: HY-P11303
• CAS No.: 161147-59-7
• Molecular Formula: C65H102N16O15
• Molecular Weight: 1347.60
• Purity: 98.28%
• Storage: Sealed storage, away from moisture. Powder -80°C, 2 years , -20°C, 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
• Solubility: ≥ 0.2 mg/mL (0.15 mM); Clear solution
• Availability: In-stock

Source

Original product source